VEGFA and age-related macular degeneration: Therapeutically, intravitreal injections with anti-vascular endothelial growth factor (anti-VEGF) have opened up a novel therapeutic universe for several relevant exudative retinal diseases, including AMD, DR, and retinal vein occlusion (RVO) since their regulatory approval in 2006 [8–10].